{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:55:42Z","timestamp":1794268542663,"version":"4.9.0"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1097\/md.0000000000006547","type":"journal-article","created":{"date-parts":[[2017,4,6]],"date-time":"2017-04-06T15:34:22Z","timestamp":1491492862000},"page":"e6547","source":"Crossref","is-referenced-by-count":9,"title":["Acquired idiopathic thrombotic thrombocytopenic purpura successfully treated with intravenous immunoglobulin and glucocorticoid"],"prefix":"10.1097","volume":"96","author":[{"given":"Hiro","family":"Nakao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Ishiguro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahoko","family":"Ikoma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Nishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chemin","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisaya","family":"Nakadate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Hayakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-29-20210309","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1182\/blood.V91.8.2839.2839_2839_2846","article-title":"Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura","volume":"91","author":"Furlan","year":"1998","journal-title":"Blood"},{"key":"R2-29-20210309","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1056\/NEJM199811263392203","article-title":"Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura","volume":"339","author":"Tsai","year":"1998","journal-title":"N Engl J Med"},{"key":"R3-29-20210309","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2141.2012.09167.x","article-title":"Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies","volume":"158","author":"Scully","year":"2012","journal-title":"Br J Haematol"},{"key":"R4-29-20210309","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1001\/archinte.1987.00370120101017","article-title":"High-dose intravenous gamma-immunoglobulin infusion in the treatment of thrombotic thrombocytopenic purpura","volume":"147","author":"Finn","year":"1987","journal-title":"Arch Intern Med"},{"key":"R5-29-20210309","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000205377","article-title":"Thrombotic thrombocytopenic purpura: report of a case with a possible response to high-dose gamma globulin","volume":"82","author":"Staszewski","year":"1989","journal-title":"Acta Haematol"},{"key":"R6-29-20210309","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1097\/00007611-199012000-00025","article-title":"Thrombotic thrombocytopenic purpura treated with high-dose intravenous gamma globulin","volume":"83","author":"Heyman","year":"1990","journal-title":"South Med J"},{"key":"R7-29-20210309","first-page":"511","article-title":"Long-lasting remission after high-dose intravenous immunoglobulins in a case of relapsing thrombotic thrombocytopenic purpura","volume":"76","author":"Castaman","year":"1991","journal-title":"Haematologica"},{"key":"R8-29-20210309","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/00000441-199302000-00007","article-title":"Case report: high-dose intravenous immunoglobulin as therapy for thrombotic thrombocytopenic purpura","volume":"305","author":"Kolodziei","year":"1993","journal-title":"Am J Med Sci"},{"key":"R9-29-20210309","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000203797","article-title":"Intravenous gamma globulin in refractory thrombotic thrombocytopenic purpura","volume":"96","author":"Nosari","year":"1996","journal-title":"Acta Haematol"},{"key":"R10-29-20210309","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3904\/kjim.2008.23.3.161","article-title":"High-dose immunoglobulin infusion for thrombotic thrombocytopenic purpura refractory to plasma exchange and steroid therapy","volume":"23","author":"Park","year":"2008","journal-title":"Korean J Intern Med"},{"key":"R11-29-20210309","first-page":"325","article-title":"Treatment of thrombotic thrombocytopenic purpura with high-dose immunoglobulins, results in 17 patients","volume":"80","author":"Centurioni","year":"1995","journal-title":"Haematlologoca"},{"key":"R12-29-20210309","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/blood-2011-03-341131","article-title":"A phase2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura","volume":"118","author":"Scully","year":"2011","journal-title":"Blood"},{"key":"R13-29-20210309","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s11239-012-0723-9","article-title":"Efficacy of rituximab in acute refractory or chronic relapsing non-familial idiopathic thrombotic thrombocytopenic purpura: a systematic review with pooled data analysis","volume":"34","author":"Tun","year":"2012","journal-title":"J Thromb Thrombolysis"},{"key":"R14-29-20210309","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1182\/blood-2014-10-559211","article-title":"The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura","volume":"125","author":"Lim","year":"2015","journal-title":"Blood"},{"key":"R15-29-20210309","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.2169\/internalmedicine.52.8253","article-title":"Therapeutic modality of 11 patients with TTP in a single institution in Miyazaki from 2000 to 2011","volume":"52","author":"Kawano","year":"2013","journal-title":"Intern Med"},{"key":"R16-29-20210309","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"key":"R17-29-20210309","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/nri3401","article-title":"Intravenous immunoglobulin therapy: how dose IgG modulate the immune system?","volume":"13","author":"Schwab","year":"2013","journal-title":"Nat Rev Immunol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000006547","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:47:03Z","timestamp":1620960423000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201704070-00029"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":17,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000006547","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]}}}